AC Immune SA · NASDAQ:ACIU

AC Immune SA — AD/PD 2024

12 slides from AC Immune SA's conference presentation, Mar 9, 2024

  1. Slide 1: VacSyn Study: Phase 2 Trial of ACI-7104.056 for Parkinson's Disease

    VACSYN STUDY: A BIOMARKER-BASED PHASE 2 CLINICAL TRIAL TO EVALUATE ACI-7104.056, A NOVEL ACTIVE IMMUNOTHERAPY FOR PARKINSON'S DISEASE Dymitr Kostrica1; Nuno Mendonça1; Jonathan Wagg1; Just Genius2; Nicolas Fournier1; Tanja Touilloux1; Erika Borcel1; Elena Valatsou2; Olivier Sol1; Valérie Hliva1; Mar

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s

  3. Slide 3: Parkinson's disease

    Parkinson’s disease Pathological deposition of alpha-synuclein Main component of Lewy bodies: Most common neurodegenerative movement disorder Alpha-synuclein Affects ~1% of the population over 65 years Halliday et al. 2011 Etiology 5-10% genetic, 90-95% idiopathic, unknown cause Cardinal motor sympt

  4. Slide 4: Active immunotherapy: clear advantages for long-term use

    Active immunotherapy: clear advantages for long-term use Provides opportunity to prevent AND treat neurodegenerative diseases globally Active immunotherapy Vaccines stimulate the patient's immune Long-lasting specific immunity for pathological target, consistent, boostable, durable system to produce

  5. Slide 5: Inhibiting of α-syn propagation to other neurons

    Inhibiting of α-syn propagation to other neurons ACI-7104.056 potential first disease – modifying active immunotherapy Active Immunotherapy ACI-7104.056 Interim analyses and decision points ■ Induces a strong IgG response against α-syn1 aggregates observed after two immunizations and Affected mainta

  6. Slide 6: Immunological potential of ACI-7104 vaccine

    Immunological potential of ACI-7104 vaccine Optimized peptide-conjugate vaccine formulation Preclinical & Antigenic Peptide Clinical Performance1 (B-cell peptide) Immunogenicity Target specificity Generates Linker target-specific Selective for aggregated α-syn antibody response Sustainability of res

  7. Slide 7: Adaptive biomarker-based Phase 2 study of ACI-7104 in early PD

    : an adaptive biomarker-based Phase 2 study of ACI-7104 in early PD1 Placebo-controlled Phase 2 Study Overview (NCT06015841) Part 1: Safety & PD2 Screening up to 8 weeks & Interim analyses ▪ Key immunogenicity measures Randomized 3:1 Treatment in PD3 Follow up (18 months) (6 months) Safety N=32 ▪ Me

  8. Slide 8: Study design

    study design double blind placebo-controlled Phase 2 study overview (NCT06015841) Key Inclusion Criteria ▪ Aged ≥40 to ≤75 years ▪ Diagnosis of clinically established early PD (confirmed by DaT-SPECT) ▪ ≤ 2 years from time of onset motor symptoms ▪ H&Y Stage I to II ▪ Monotherapy treatment with L-Do

  9. Slide 9: Baseline characteristics of trial

    Baseline characteristics of trial Variable Unit Total Dat-SCAN type vs Hoehn and Yahr stage Total number of patients n 26 Age (years) (mean (std) mean (std) 62.2 (7.34) Adapted from A .Antonini, et al. 2004 Sex Male n (%) 16 (61.5%) Female n (%) 10 (38.5%) Hoehn and Yahr stage Stage I n (%) 8 (30.7%

  10. Slide 10: Blinded Treatment-Emergent Adverse Events (TEAE) Summary

    Blinded Treatment-Emergent Adverse Events (TEAE) Summary1 1 No deaths 2 No other Serious TEAEs No TEAEs Leading to Discontinuation from the 3 Study Most common TEAEs were Injection Site 4 Reactions (e.g. redness, itching) 5 All TEAEs mild or moderate in severity Up to the present date, no significan

  11. Slide 11: Conclusions

    Conclusions ▪ Phase 2 study in early PD subjects is based on an innovative two-part trial design ▪ The approach is designed for early de-risking and simultaneously to allow for fast acceleration and enables a rapid entry into a pivotal clinical phase. ▪ Targeting early PD population ▪ Good safety an

  12. Slide 12: Acknowledgements

    Dymitr Kostrica Günther Staffler Nuno Mendonça Marie Kosco-Vilbois Jonathan Wagg Andrea Pfeifer Just Genius Nicolas Fournier Tanja Touilloux Erika Borcel Elena Valatsou Olivier Sol Valérie Hliva Marija Vukicevic We want to thank the study participants, their families for their participation and comm

AC Immune — AD/PD 2024 on 6ix